We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $12.11 · 9 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties (NASDAQ:BCYC) - Seeking Alpha
Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties (NASDAQ:BCYC) Seeking Alpha
Bicycle Therapeutics: Riding Toward A New Frontier In Precision-Guided Cancer Medicines? - RTTNews
Bicycle Therapeutics: Riding Toward A New Frontier In Precision-Guided Cancer Medicines? RTTNews
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
Bicycle Therapeutics sharpens new weaponry to fight bladder cancer - Business Weekly
Bicycle Therapeutics sharpens new weaponry to fight bladder cancer Business Weekly
Bicycle Therapeutics Presents Promising Duravelo-2 Phase 2 Data for Zelenectide Pevedotin in Metastatic Urothelial Cancer at 2026 ASCO Annual Meeting - Minichart
Bicycle Therapeutics Presents Promising Duravelo-2 Phase 2 Data for Zelenectide Pevedotin in Metastatic Urothelial Cancer at 2026 ASCO Annual Meeting Minichart
Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC) - Stock Titan
Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC) Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 30. | After market close (AMC) | $-0.58 | — | — | $4.35M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.88 | — | — | $9.98M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-2.15 | — | — | $31.57M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-1.4 | — | — | $28.89M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 08. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
| 2026. 03. 19. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 132,032 | $934.79M | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 164,800 | $764.67M | 0.00% | — | New position |
See new positions, full exits, and weight changes.